Study Title
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma (NCT00099255)
Trial Description
This multi-center, phase II study will be conducted to define the toxicity profile and antitumor activity of the antibody-drug conjugate SGN-30 in patients with pcALCL and other closely related lymphoproliferative disorders.
This trial is sponsored by Seattle Genetics. [1]
Study Data
- Condition: Large Cell Lymphoma
- Interventions:
- Drugs used in this trial
- SGN-30
- Drugs used in this trial
- Phase: II
- Estimated Enrollment: 40
- Start: September 2004
- Completion: February 2007
- Last verified: December 2014
Study Schematic
Click here to Return to Drug map
Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.
